Form Health’s Post

The conversation around treatment of obesity and GLP1 receptor agonist medications is expanding, as we learn more about the broad health benefits of these drugs in people with obesity. Exciting (though early) results from Eli Lilly's SUMMIT phase 3 trial have been previewed. In adults with obesity and heart failure with preserved ejection fraction (HFpEF) tirzepatide significantly improved heart failure outcomes such as symptoms, activity limitations and quality of life.  We eagerly await more detailed results and peer reviewed publication. Semaglutide has also shown very positive outcomes in this population of patients. So we may be looking at yet another future indication for GLP-1s, the treatment of heart failure in people with obesity. All of these clinical trials continue to support turning the conversation from weight loss as a cultural and cosmetic issue to treating obesity for its many many benefits to health. It is exciting to see so much emerging research supporting the concept that treating obesity is at the hub of -and a very effective approach to - treating cardio-metabolic disease.

📢 Exciting New Research on Weight Loss Treatments! 📢 A recent study published in JAMA Internal Medicine has made significant strides in the ongoing battle against overweight and obesity. Researchers from Truveta Inc, Bellevue, Washington, led by Patricia J. Rodriguez, conducted a head-to-head comparison of semaglutide and tirzepatide, two medications labeled for type 2 diabetes (T2D), to determine their effectiveness in weight loss. Key Findings: Weight Loss Effectiveness: - Tirzepatide demonstrated significantly greater weight loss than semaglutide: - ≥5% weight loss: hazard ratio (HR) 1.76 - ≥10% weight loss: HR 2.54 - ≥15% weight loss: HR 3.24 Weight Reduction Over Time: - At 3 months: -2.4% - At 6 months: -4.3% - At 12 months: -6.9% Adverse Events: - Rates of gastrointestinal adverse events were similar between the two groups. This study suggests that tirzepatide may offer a more effective option for weight loss in adults with overweight or obesity compared to semaglutide. These results could have significant implications for clinical practice and patient outcomes. We look forward to further research exploring other important outcomes related to these treatments. Click on the link to dive deep into the research article. #WeightLoss #Obesity #Healthcare #Pharmaceuticals #ClinicalResearch #Tirzepatide #Semaglutide #DiabetesResearch #HealthInnovation https://lnkd.in/eQFKXCkG

In the phase 3 SUMMIT trial, Lilly's tirzepatide reduced the risk of adverse Heart Failure outcomes such as hospitalization or cardiovascular death by 38% compared with placebo. Published: August 1, 2024. https://lnkd.in/gCWWDe_J ▪️Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death – by 38% compared to placebo ▪️Tirzepatide significantly improved heart failure symptoms and physical limitations ▪️Tirzepatide led to 15.7% weight loss in a combined population of people with and without type 2 diabetes #Heart failure with preserved ejection fraction (#HFpEF) is a condition in which the heart's left pumping chamber becomes stiff and unable to fill properly. It is associated with a high burden of symptoms and physical limitations affecting daily life, including fatigue, shortness of breath, reduced ability to exercise and swelling of extremities. #Tirzepatide is a once-weekly #GIP (glucose-dependent insulinotropic polypeptide) receptor and #GLP1 (glucagon-like peptide-1) receptor agonist. regulatory agencies earlier this year. ®® Tirzepatide was approved by the #FDA as #Mounjaro for adults with type 2 #diabetes to improve glycemic control on May 13, 2022, and as #Zepbound for adults with #obesity (a BMI of 30 kg/m or greater) or those who are #overweight (a BMI of 27 kg/m or greater) who also have a weight-related #omorbid condition on November 8, 2023. Both Mounjaro and Zepbound should be used as an #adjunct to #diet and #exercise. "HFpEF accounts for nearly half of all heart failure cases, and in the U.S. almost 60% of those impacted also live with obesity. Despite a continuing increase in the number of people with both HFpEF and obesity, treatment options remain limited" said Jeff Emmick, MD, PhD, senior vice president, product development, Lilly. "Previous incretin studies in this population focused on symptoms and physical limitations. In a first-of-its-kind trial, tirzepatide reduced severity of symptoms and improved heart failure outcomes in people with HFpEF and obesity." The trial, which included 731 patients with or without diabetes from US, Argentina, Brazil, China, India, Israel, Mexico, Puerto Rico, Russia, and Taiwan, also met all key secondary endpoints, including longer 6-minute walk-test distance, lower level of high-sensitivity C-reactive protein, and reduced body weight through 1 year. https://lnkd.in/guRFMetV

🔬 𝐁𝐫𝐢𝐝𝐠𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐚𝐩 - 𝐖𝐨𝐦𝐞𝐧'𝐬 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐍𝐞𝐞𝐝𝐬 𝐒𝐭𝐢𝐥𝐥 𝐎𝐯𝐞𝐫𝐥𝐨𝐨𝐤𝐞𝐝 𝐢𝐧 𝟐𝟎𝟐𝟒 🔬 A Daiichi Sankyo-funded study highlights significant gender disparities in cardiovascular treatment across Europe, with women less likely than men to receive appropriate lipid-lowering therapies and achieve LDL cholesterol targets. 👇 Read the article below for the full story 👇 https://lnkd.in/eJdXQaFu

An Obesity Drug Prevents Covid Deaths, the provocative new clinical study explained in layman terms. 'Wegovy, the popular obesity drug, may have yet another surprising benefit. In a large clinical trial, people taking the drug during the pandemic were less likely to die of Covid-19, researchers reported on Friday. People on Wegovy still got Covid, and at the same rate as people randomly assigned to take a placebo. But their chances of dying from the infection plunged by 33 percent, the study found. In addition, the death rate from all causes was lower among subjects taking Wegovy, a very rare finding in clinical trials of new treatments. The result suggests that lower life expectancy among people with obesity is actually caused by the disease itself, and that it can be improved by treating obesity. “Stunning,” Dr. Jeremy Faust, an emergency room physician at Brigham and Women’s Hospital who wrote an editorial accompanying the study, said of the data. The study was published in The Journal of the American College of Cardiology. The study was not originally designed to look at the effects of taking Wegovy on people with Covid. But the participants taking the drug were not healthier than the others, said Dr. Harlan Krumholz, a cardiologist at Yale and the editor in chief of the journal. “It is a randomized trial and the infection rates were similar, so this represents top-notch evidence,” he said. The obesity drug also reduced the overall death rate by 19 percent, the researchers reported. Although it was known that people with obesity have shortened life spans, this is the first rigorous study to show that treating obesity itself helps people live longer.' Harlan Krumholz Jeremy Faust JACC Journals https://lnkd.in/ePpFvYi5

We have seen the benefit of adding GIP agonism on top of GLP-1 action with Tirzepatide. Looking into the future, this comparative overview indicates that Maritide, combining stable GLP-1 agonist moiety with GIP receptor antagonist may be even more effective!

Good morning network ☕ Vivani Medical’s New Trial Shakes Up Obesity Treatment! Vivani made headlines in the fight against obesity with the announcement of a groundbreaking clinical trial for their GLP-1 implant. The LIBERATE-1 trial, set to begin in late 2024, will be conducted in Australia. It aims to assess the safety, tolerability, and pharmacokinetics of Vivani’s subdermal exenatide implant in obese and overweight individuals. The technology behind Vivani’s implant is revolutionary, as it provides an alternative to the more frequent dosing of drugs like semaglutide. The implant could potentially reduce the treatment burden by requiring only twice-yearly administrations, while delivering similar results in terms of weight loss. This development marks a significant step forward in obesity treatment, aiming to offer a long-lasting, convenient option for patients. The first results from the trial are expected in 2025, making it an exciting time for both Vivani and the biotech industry at large. Their innovative approach brings new hope to millions struggling with obesity, and the LIBERATE-1 trial is a major stride toward reshaping long-term treatment strategies Congratulations to Vivani on this critical milestone!

🔬 Exciting News Alert! 🔬 We're thrilled to share that Regor Therapeutics has initiated Phase II clinical trials for their innovative obesity treatment, RGT-075. Here at Synergy Healthcare, we're dedicated to advancing research in metabolic diseases, and we're proud to see promising developments like this in the field. RGT-075, an oral GLP-1 agonist, holds immense potential for adults struggling with obesity or overweight conditions with weight-linked comorbidities. This randomized, multicentre trial, involving nearly 60 adult subjects, will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RGT-075 compared to a placebo. The 12-week treatment regimen, including a titration period and a target dose phase, is a crucial step towards providing effective and convenient solutions for individuals battling obesity. Regor Therapeutics' commitment to innovation, demonstrated through their rCARD platform, is truly commendable. With a pipeline focused on metabolic diseases like type-2 diabetes mellitus and obesity, their efforts align perfectly with our mission at Synergy Healthcare. We eagerly anticipate the topline data from this Phase II trial, expected in the second half of this year, which could potentially pave the way for a new era in obesity treatment. Congratulations to the team at Regor Therapeutics on reaching this significant milestone! Together, we're driving advancements in healthcare and striving to make a meaningful impact in the lives of patients worldwide. #ClinicalResearch #ObesityTreatment #MetabolicDiseases #Innovation #PhaseIITrial #Healthcare #SynergyHealthcare 🔗 https://lnkd.in/dJvF3CTm